Skip to main content
. 2022 Mar 24;78:103964. doi: 10.1016/j.ebiom.2022.103964

Figure 4.

Fig 4

Kaplan-Meier Time-to-First Event Curves of DNMT3A or TET2 Separately for Death and MACE. No matter patients with DNMT3A- (a, b) (no-DNMT3A VAF≥2% group, n = 444; DNMT3A VAF≥2% group, n = 41) or TET2- (c,d) (no-TET2 VAF≥2% group, n = 460; TET2 VAF≥2% group, n = 25) CH-driver mutations with a VAF≥2% had higher incidence of death and MACE. P-values are for log-rank tests.